ATE192499T1 - Herstellung rekombinanter proteine unter verwendung von herpes-virus-promotoren und vp16- transaktivatoren - Google Patents

Herstellung rekombinanter proteine unter verwendung von herpes-virus-promotoren und vp16- transaktivatoren

Info

Publication number
ATE192499T1
ATE192499T1 AT93870043T AT93870043T ATE192499T1 AT E192499 T1 ATE192499 T1 AT E192499T1 AT 93870043 T AT93870043 T AT 93870043T AT 93870043 T AT93870043 T AT 93870043T AT E192499 T1 ATE192499 T1 AT E192499T1
Authority
AT
Austria
Prior art keywords
transactivators
production
recombinant proteins
herpes virus
virus promoters
Prior art date
Application number
AT93870043T
Other languages
English (en)
Inventor
Maureen Katherine Highkin
Paul Jerome Hippenmeyer
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Application granted granted Critical
Publication of ATE192499T1 publication Critical patent/ATE192499T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035—Herpes simplex virus I or II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT93870043T 1992-03-13 1993-03-12 Herstellung rekombinanter proteine unter verwendung von herpes-virus-promotoren und vp16- transaktivatoren ATE192499T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85070092A 1992-03-13 1992-03-13

Publications (1)

Publication Number Publication Date
ATE192499T1 true ATE192499T1 (de) 2000-05-15

Family

ID=25308883

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93870043T ATE192499T1 (de) 1992-03-13 1993-03-12 Herstellung rekombinanter proteine unter verwendung von herpes-virus-promotoren und vp16- transaktivatoren

Country Status (10)

Country Link
US (1) US6635478B1 (de)
EP (1) EP0566554B1 (de)
JP (1) JPH067174A (de)
AT (1) ATE192499T1 (de)
CA (1) CA2092645A1 (de)
DE (1) DE69328514T2 (de)
DK (1) DK0566554T3 (de)
ES (1) ES2049691T3 (de)
GR (1) GR3033939T3 (de)
PT (1) PT566554E (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
DK0468257T3 (da) * 1990-07-20 2000-03-27 Bayer Ag Multimer form af human rhinovirusreceptorprotein
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
GB9700411D0 (en) * 1997-01-10 1997-02-26 Univ London Eukaryotic gene expression cassette and uses thereof
CA2223032A1 (en) * 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
DE60141976D1 (de) * 2000-11-29 2010-06-10 Univ Rochester Helfervirus-freie herpesvirus-amplifikatpartikel und deren verwendungen
US8092791B2 (en) * 2001-05-23 2012-01-10 University Of Rochester Method of producing herpes simplex virus amplicons, resulting amplicons, and their use
EP1532254A4 (de) * 2002-05-31 2006-05-10 Univ Rochester Virusfreie helfer-herpesvirus-amplicon-teilchen und ihre verwendungszwecke
EP1592455A4 (de) * 2003-01-23 2006-06-28 Univ Rochester Herpesvirus-amplicon-teilchen
EP1682171A4 (de) * 2003-11-07 2008-02-27 Univ Rochester Zusammensetzungen und verfahren zur behandlung von neurologischen erkrankungen
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
AU2006255167A1 (en) * 2005-06-03 2006-12-14 University Of Rochester Herpes virus-based compositions and methods of use
WO2006135602A2 (en) * 2005-06-03 2006-12-21 University Of Rochester Herpes virus-based compositions and methods of use in the prenatal and perinatal periods
SI2516629T1 (sl) * 2009-12-21 2016-10-28 The Brigham And Women's Hospital, Inc. Cepiva proti virusu herpes simplex
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4740461A (en) * 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4738922A (en) * 1984-05-25 1988-04-19 Dana Farber Cancer Institute Trans-acting transcriptional factors
JPH02502605A (ja) * 1987-03-13 1990-08-23 シェリング・コーポレーション 遺伝子発現の刺激方法
EP0291893A1 (de) * 1987-05-19 1988-11-23 The Du Pont Merck Pharmaceutical Company Stabile menschliche Zellinien, die ein Indikatorgenprodukt unter virusspezifischen genetischen Kontrollen exprimieren
US5026635A (en) * 1987-05-19 1991-06-25 Du Pont Merck Pharmaceutical Stable human cell lines expressing an indicator gene product under virus-specific genetic controls
EP0327960A1 (de) * 1988-02-11 1989-08-16 F. Hoffmann-La Roche Ag Sekretierbare Formen von alkalischer Phosphatase
GB8900483D0 (en) * 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
CA2063822C (en) * 1989-07-18 2006-10-03 J. Gordon Foulkes Method of transcriptionally modulating gene expression and of discovering chemicals capable of functioning as gene expression modulators
EP0455424A3 (en) * 1990-05-02 1992-04-29 Merck & Co. Inc. Mammalian inducible promoter cascade system

Also Published As

Publication number Publication date
DK0566554T3 (da) 2000-08-07
DE69328514T2 (de) 2001-01-11
ES2049691T3 (es) 2000-10-16
PT566554E (pt) 2000-09-29
GR3033939T3 (en) 2000-11-30
ES2049691T1 (es) 1994-05-01
DE69328514D1 (de) 2000-06-08
CA2092645A1 (en) 1993-09-14
US6635478B1 (en) 2003-10-21
EP0566554B1 (de) 2000-05-03
EP0566554A3 (de) 1994-01-05
EP0566554A2 (de) 1993-10-20
JPH067174A (ja) 1994-01-18

Similar Documents

Publication Publication Date Title
DE69328514T2 (de) Herstellung rekombinanter Proteine unter Verwendung von Herpes-Virus-Promotoren und VP16-Transaktivatoren
ES8305413A1 (es) Un metodo para estabilizar y seleccionar celulas huesped quecontienen un adn recombinante
CA2193094A1 (en) The cytoplasmic inhibition of gene expression
AU1851895A (en) Host-vector system for use in gene therapy
AU553885B2 (en) Expression of exogenous polypeptides in yeast
DE3888561T2 (de) Hohe Proteinsyntheserate in Hefe.
GB8718779D0 (en) Dna sequence & expression vector
ATE34770T1 (de) Dna-vektoren und ihre verwendung in der rekombinanten dna-technologie.
KR840005745A (ko) B형 간염비루스 유전자를 삽입한 조환 플라스미드, 이 조환 플라스미드로 전환된 효모 및 b형 간염비루스 표면항원의 제조방법
AU3668389A (en) Exogenous gene expression vector containing chick beta-actin gene promoter
EP0911412A4 (de) Vektor zum gentransfer in pflanzen erlaubt mögliche deletion des markergens
CA2037677A1 (en) Process for production of exogenous gene or its product in plant cells
EP0363127A3 (de) Expression in Eukaryoten
ATE72837T1 (de) Vielfach amplifizierbare vektoren fuer hohe expression exogener dns.
AU657929B2 (en) Method of producing pathogen-resistant plants
KR970010968A (ko) 오리 배 세포를 이용한 에리스로포이틴의 발현 시스템
CA2121481A1 (en) Expression of polypeptides in e.coli under control of the e.coli mdh-gene promoter
ATE250670T1 (de) Vektor, enthält ein bei arn-polymerase-iii transcriptes virus-gen
DE58909205D1 (de) Expressionsvektor und Verfahren zur regulierbaren Herstellung von Proteinen in Eukaryonten.
CA2309028A1 (en) The cytoplasmic inhibition of gene expression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee